Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles

Vaccine, Journal Year: 2024, Volume and Issue: 46, P. 126668 - 126668

Published: Dec. 30, 2024

Language: Английский

---

Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original antigenic sin

Research Square (Research Square), Journal Year: 2023, Volume and Issue: unknown

Published: Nov. 29, 2023

Abstract Several studies have suggested the imprinting of SARS-CoV-2 immunity by original immune challenge without addressing formation de novo response to successive antigen exposures. As this is crucial for development antigenic sin, we assessed against mutated epitopes omicron after vaccine breakthrough. Our data demonstrated a robust humoral in thrice-vaccinated individuals following breakthrough which was recall vaccine-induced memory. The and memory B cell responses altered regions surface proteins were impaired. T spike protein present due high cross-reactivity cells rather than response. findings, therefore, underpin speculation that vaccination may lead sin if future variants overcome immunity.

Language: Английский

---

What type of vaccine immunity controls breakthrough COVID?

Vaccine Insights, Journal Year: 2023, Volume and Issue: 02(08), P. 317 - 321

Published: Aug. 23, 2023

VIEWPOINT "There is interest in the possibility of developing mucosally targeted vaccines hope these may increase mucosal antibody levels, improve protection and reduce shedding virus..."

Language: Английский

---